UK unveils post-Brexit medical device overhaul with new MHRA framework

The UK government published comprehensive plans on 13 June 2026 for a new regulatory framework governing medical devices, marking a significant departure from European Union rules following Brexit. The Medicines and Healthcare products Regulatory Agency (MHRA) will introduce fresh product marking systems and updated safety requirements, with implementation beginning in 2027.

New Framework Details

The regulatory overhaul encompasses AI-powered medical tools alongside traditional devices, establishing updated performance standards and post-market surveillance requirements. Ministers emphasise the reforms will accelerate access to innovative technologies whilst maintaining patient safety standards, positioning Britain as a more attractive market for medical technology companies.

The package introduces specific provisions for software as a medical device, reflecting the growing role of digital health tools in modern healthcare. Manufacturers will face tighter obligations to report safety concerns and take corrective action when issues arise. The new system establishes three risk categories for medical devices, with Class III devices requiring the most stringent pre-market assessment procedures.

Under the framework, manufacturers must demonstrate clinical evidence for device safety and effectiveness through expanded trial requirements. The MHRA will also introduce mandatory cybersecurity standards for connected medical devices, addressing growing concerns about potential vulnerabilities in networked healthcare equipment.

Industry Response

Industry groups have broadly welcomed the regulatory clarity after years of uncertainty following Brexit. The Association of British HealthTech Industries described the framework as "pragmatic and science-based," though warned that implementation costs could burden smaller companies.

Trade associations have cautioned that smaller companies will require support to manage transition costs and navigate parallel compliance with both EU and UK regulatory regimes. The British In Vitro Diagnostics Association estimates that dual compliance could increase regulatory costs by 40-60% for companies serving both markets.

Several major medical device manufacturers have already committed to establishing UK-specific regulatory teams to manage the transition. Johnson & Johnson and Medtronic have announced plans to expand their British operations to accommodate the new requirements, whilst some smaller European firms are considering whether to maintain UK market access.

The phased implementation approach aims to give manufacturers time to adapt their processes and certification procedures to meet the new British standards. Companies currently operating under EU medical device regulations will need to transition to the MHRA system over the coming years, with grace periods varying by device category.

Scottish Implications

Scottish life sciences firms, particularly those in the central belt's biotech corridor, face decisions about which regulatory pathway to prioritise. Companies exporting to European markets may need to maintain dual compliance systems, potentially increasing operational costs for smaller Scottish manufacturers.

Edinburgh-based diagnostic company Omega Diagnostics has indicated it will seek both UK and EU approvals for new products, describing the dual pathway as "commercially necessary but operationally challenging." Glasgow's medical technology cluster, home to over 200 companies, is establishing shared resources to help smaller firms navigate the regulatory transition.

NHS Scotland trusts will need to ensure procurement processes align with the new MHRA requirements when purchasing medical devices and AI diagnostic tools. The changes could affect the timeline for introducing innovative medical technologies in Scottish hospitals, depending on manufacturers' certification priorities.

Scotland's universities and research institutions, which collaborate extensively on medical device development, may need to adjust their commercialisation strategies to account for the diverging regulatory landscape between the UK and EU. The University of Strathclyde's Biomedical Engineering department is already revising its industry partnership agreements to reflect the new regulatory requirements.

Implementation Timeline and Next Steps

The MHRA will begin accepting applications under the new framework from early 2027, with existing EU-certified devices granted transition periods to achieve UK compliance. The agency plans to publish detailed guidance documents throughout 2026 to help manufacturers prepare for the changes, starting with draft guidelines for AI-based diagnostic tools in September.

Software-based medical devices and AI diagnostic tools will be subject to particularly rigorous assessment procedures, reflecting concerns about algorithmic bias and patient safety in digital health applications. The MHRA is recruiting additional specialist reviewers with expertise in artificial intelligence and machine learning to handle these complex assessments.

The government has allocated £50 million over three years to support the MHRA's expanded regulatory capacity, including new laboratories and digital infrastructure for processing applications. Industry consultation periods will run through autumn 2026, with final regulations expected by December.

The BBC reports that the government expects the new system to be fully operational by 2028, replacing the current temporary arrangements that have been in place since Brexit. The MHRA anticipates processing approximately 2,000 device applications annually once the system reaches full capacity.

The regulatory divergence represents another step in Britain's post-Brexit regulatory independence, though it creates additional complexity for companies operating across both UK and European markets. Success will depend on the MHRA's ability to process applications efficiently while maintaining the safety standards that underpin public confidence in medical devices. Early indicators suggest the agency is prioritising digital infrastructure investments to streamline approval processes and reduce assessment timelines compared to current EU procedures.